Gilead Sciences, Inc. (GILD)
146.76
+0.64
(+0.44%)
USD |
NASDAQ |
Aug 24, 16:00
146.50
-0.26
(-0.18%)
After-Hours: 20:00
Gilead Sciences Debt to Equity Ratio : 2.219 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.219 |
| March 31, 2026 | 0.943 |
| December 31, 2025 | 1.125 |
| September 30, 2025 | 1.158 |
| June 30, 2025 | 1.268 |
| March 31, 2025 | 1.302 |
| December 31, 2024 | 1.414 |
| September 30, 2024 | 1.258 |
| June 30, 2024 | 1.277 |
| March 31, 2024 | 1.436 |
| December 31, 2023 | 1.124 |
| September 30, 2023 | 1.120 |
| June 30, 2023 | 1.193 |
| March 31, 2023 | 1.202 |
| December 31, 2022 | 1.188 |
| September 30, 2022 | 1.196 |
| June 30, 2022 | 1.296 |
| March 31, 2022 | 1.315 |
| December 31, 2021 | 1.295 |
| September 30, 2021 | 1.290 |
| June 30, 2021 | 1.532 |
| March 31, 2021 | 1.592 |
| December 31, 2020 | 1.764 |
| September 30, 2020 | 1.679 |
| June 30, 2020 | 1.337 |
| Date | Value |
|---|---|
| March 31, 2020 | 1.092 |
| December 31, 2019 | 1.124 |
| September 30, 2019 | 1.228 |
| June 30, 2019 | 1.178 |
| March 31, 2019 | 1.234 |
| December 31, 2018 | 1.278 |
| September 30, 2018 | 1.195 |
| June 30, 2018 | 1.341 |
| March 31, 2018 | 1.411 |
| December 31, 2017 | 1.641 |
| September 30, 2017 | 1.178 |
| June 30, 2017 | 1.160 |
| March 31, 2017 | 1.288 |
| December 31, 2016 | 1.395 |
| September 30, 2016 | 1.605 |
| June 30, 2016 | 1.424 |
| March 31, 2016 | 1.703 |
| December 31, 2015 | 1.190 |
| September 30, 2015 | 1.276 |
| June 30, 2015 | 0.754 |
| March 31, 2015 | 0.7203 |
| December 31, 2014 | 0.8051 |
| September 30, 2014 | 0.6957 |
| June 30, 2014 | 0.5929 |
| March 31, 2014 | 0.7357 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Vertex Pharmaceuticals, Inc. | 0.0977 |
| AbbVie, Inc. | -11.93 |
| Regeneron Pharmaceuticals, Inc. | 0.0854 |
| Amgen, Inc. | 4.903 |
| Biogen, Inc. | 0.4433 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 49.36B |
| Total Liabilities (Quarterly) | 37.62B |
| Shareholders Equity (Quarterly) | 11.83B |
| Current Ratio | 1.266 |
| Net Debt Paydown Yield | -0.17% |